{
  "abstract": "Background/Objectives: The optimal adjuvant chemotherapy regimen remains uncertain for some patients with hormone receptor (HR)-positive/HER2-negative early breast cancer, particularly regarding the incremental benefit of anthracyclines. We compared real-world outcomes with docetaxel-plus-cyclophosphamide (TC) and anthracycline–taxane chemotherapy. Methods: This retrospective single-center cohort included patients with stage I–III HR-positive/HER2-negative breast cancer who underwent surgery and received adjuvant TC or anthracycline–taxane chemotherapy between 2019 and 2025. Patients receiving neoadjuvant systemic therapy were excluded. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Propensity score overlap weighting adjusted for measured baseline differences was used; the absolute difference in weighted 3-year DFS was the primary adjusted measure. Results: Among 361 patients, 201 received TC and 160 anthracycline–taxane chemotherapy. The anthracycline–taxane group had higher baseline clinicopathologic risk. Median follow-up was 39.0 months. Twelve DFS events occurred (TC, n = 3; anthracycline–taxane, n = 9). Unadjusted 3-year DFS was 99.0% versus 96.6% (p = 0.096), and 3-year OS was 99.4% versus 99.1% (p = 0.725). The overlap-weighted analysis included 346 patients and achieved adequate covariate balance. Weighted 3-year DFS was 99.2% with TC and 96.5% with anthracycline–taxane chemotherapy, an absolute difference of 2.68 percentage points (95% CI, −1.81 to 10.03). Sensitivity analysis yielded similar results (2.70 percentage points; 95% CI, −1.76 to 9.87). Conclusions: No statistically significant difference in 3-year DFS was demonstrated after adjustment. Limited events and relatively short follow-up preclude conclusions regarding equivalence or noninferiority. These findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Perihan Perkin",
      "orcid": "0000-0003-3994-815X"
    },
    {
      "affs": [
        0
      ],
      "name": "Derya Sarikaya",
      "orcid": "0000-0003-2127-8004"
    },
    {
      "affs": [
        0
      ],
      "name": "Hilal Karakas"
    },
    {
      "affs": [
        0
      ],
      "name": "Ugur Ozberk",
      "orcid": "0009-0005-9030-022X"
    },
    {
      "affs": [
        0
      ],
      "name": "Burak Bilgin"
    },
    {
      "affs": [
        0
      ],
      "name": "Efnan Algin",
      "orcid": "0000-0002-8917-9267"
    },
    {
      "affs": [
        0
      ],
      "name": "Oznur Bal",
      "orcid": "0000-0002-6901-2646"
    },
    {
      "affs": [
        0
      ],
      "name": "Didem Sener Dede"
    },
    {
      "affs": [
        0
      ],
      "name": "Gokhan Ucar",
      "orcid": "0000-0002-7649-1075"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4rpy054k88mgd.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15218568",
  "fulltext_url": null,
  "id": "4rpy054k88mgd",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://www.mdpi.com/2077-0383/15/21/8568",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-03",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/4rpy054k88mgd.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:21:42Z",
      "native_id": "10.3390/jcm15218568",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/21/8568"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study",
  "title_text": "Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T00:21:25Z",
  "url": "https://research.draconitic.com/paper/4rpy054k88mgd",
  "venue": "Journal of Clinical Medicine",
  "versions": []
}